Paclitaxel-Coated Devices Don’t Carry Excess Mortality Risk, FDA Says

After analyzing four additional years of data, the FDA has decided to reverse its 2019 judgment of the mortality risk of paclitaxel-coated devices, saying data do not support a finding of excess mortality risk.
Source: Drug Industry Daily